PhARMA Innovation Forum (PIF) and its 26 biopharmaceutical member companies express their deep concern over the impasse regarding patient access to innovative therapies. According to official data from the National Central Purchasing Body for Health Sector (EKAPY), shared with our companies and covering the first half of 2023, the mandatory clawbacks due to budget overruns…
Το ζήτημα της δημόσιας χρηματοδότησης της φαρμακευτικής δαπάνης αναδεικνύει ως πρωτεύουσας σημασίας και ύψιστης προτεραιότητας για την άνθιση της καινοτομίας στη φαρμακοβιομηχανία, η κυρία Λαμπρίνα Μπαρμπετάκη, πρόεδρος του PhARMA Innovation Forum (PIF) Greece. Η κυρία Μπαρμπετάκη, που είναι η πρόεδρος και διευθύνουσα σύμβουλος στην AbbVie Pharmaceuticals για την Ελλάδα, Κύπρο και Μάλτα, μίλησε στο Αφιέρωμα του…
A new Board of Directors was elected by the General Assembly of the members of PhARMA Innovation Forum (PIF) Greece, held yesterday. The new Board came together earlier today for the first time to assign internal roles and responsibilities. As a result of this procedure, Labrina Barmpetaki, President & Managing Director, Abbvie Pharmaceuticals Greece, Cyprus…
Innovation plays a key role in all areas of human activity. However, its contribution to the health sector, especially after the COVID-19 pandemic, is now indisputable. As the General Manager of PhARMA Innovation Forum Greece, Mariangela Ekonomopoulou, tells NEWS247: «The enormous positive impact of innovation on people’s lives is additionally attested by the increase in…
The debate on the contribution of the private health sector to society, the national economy and entrepreneurship is an excellent occasion not so much to record the multiple benefits coming from this contribution, but mainly to start a meaningful dialogue around its limits, i.e. around the required balance between the private and public sectors in…
Τhe series of closed working sessions within the framework of the “Meeting Patients’ Needs” initiative, recently announced by the PhARMA Innovation Forum Greece continued with Hematology. At the center of the discussion were the particularities of the journey of the patients of the specific therapeutic category and their needs regarding both access to their treatments…
